Advertising

NYSE:NVS

83.15
0.81 (0.98%) 1d
0
Showing 1 to 15 of 41 entries
SELL
It can't break above $90. He likes a half-dozen drug companies better.
biotechnology / pharmaceutical
TOP PICK
A joint pharmaceutical company that has two businesses: branded and generic. The generic side will be very interesting post-covid when countries will be indebted and must provide cost-effective health care. The product pipeline looks reasonable. 6% dividend growth in the past 10 years. A safe steady growth opportunity. (Analysts’ price target is $102.00)
biotechnology / pharmaceutical
DON'T BUY
He sold it recently. They sold their eye-care division and are back to generic drugs, a lousy business for all companies. Invest elsewhere.
biotechnology / pharmaceutical
HOLD

$200 billion market cap. Fifty + drugs. None of them s over 6.5% of their revenue. They are spinning their ophthalmology business. Some positives there. He struggles to understand why the stock is down. Wouldn’t be his favorite European exposure but still well diversified solid business.

biotechnology / pharmaceutical
BUY

He likes it because of its exposure to Entresto, which cardiologists often call a wonder drug. The drug is relatively expensive ($9 per day) so the issue is getting insurance companies to pay for it. He thinks the runway for the drug is excellent and that it will become a blockbuster within a year or two. Pharma companies are under pressure because Trump is currently talking about reducing drug prices, but he (Grammer) is willing to wait on this stock.

biotechnology / pharmaceutical
TOP PICK

It is a very big company with a pipeline of 13 drugs that are close to approves that could be blockbusters. They have drugs for heart failure that cardiologists are keen on. They have an eye care drug. They have a nice mixture of health care drugs. Pharma is unloved but that is an opportunity he can see. (Analysts’ target: $93.00).

biotechnology / pharmaceutical
COMMENT

This has 3 things going for it. It is an international stock being Swedish, and European stocks have been stronger than US stocks for the 1st time in 10 years, and that should continue. Secondly, it is in healthcare which he likes. Thirdly, they’ve been doing a lot of research in immune boosting therapy, helping people fight cancer. This is going to be huge as we have so much further to go in fighting this scourge.

biotechnology / pharmaceutical
HOLD

They are joint ventured with Merck. Their oncology business is growing. Their dividend is stable. They are big pharma and you won’t see as much growth out of it. He is in it for the dividend.

biotechnology / pharmaceutical
COMMENT

A value play that is run out of Switzerland with about a $200 billion market cap. There are 3 drivers to their business. There is the long-standing pharmaceuticals, they have the bio similar business, as well as Alcon for contact lenses. He likes the diversity. They have some key catalysts over the next couple of quarters. They are lacking in immuno ecology, cancer research, and there is speculation that they may sell one of their businesses in order to make an acquisition. Trading at 16X this year and down to just under 15X next year. Stable dividend. He likes this one very much.

biotechnology / pharmaceutical
WATCH

The global pharma industry is under this cloud. The whole subsector is really struggling. They have come off their bottoms, but are working hard going sideways until we get more clarity on healthcare in the US.

biotechnology / pharmaceutical
BUY

It is a really strong global pharma company. They are turning around their eye care business acquisition and their cardiac drug which had a bungled launch. If they are successful they will do quite well. It could be a blockbuster.

biotechnology / pharmaceutical
WAIT

Thinks pharmaceuticals had a rough bit of water, is the politics in the US. It hasn’t been resolved as to who is going to win. There has also been a lot of negativity around Valeant (VRX-N) and the whole sector, which is not done yet. Mrs. Clinton said she is going to clean this up. He would have a tendency to move his money somewhere else where there is more security.

biotechnology / pharmaceutical
BUY

60% of their business is in pharmaceuticals, 20% in ophthalmology and 20% in Sandoz, a biosimilar company, the 1st one to get a biosimilar approved in the US. Attractive balance sheet.

biotechnology / pharmaceutical
PAST TOP PICK

(A Top Pick March 13/15. Down 22.73%.) This had swapped its businesses with Glaxo and the market didn’t like it. Also, there is a problem with the Swiss franc. However, you are still getting a 3.9% yield. A well-run drug company.

biotechnology / pharmaceutical
PARTIAL BUY

Suffering on the Pharma side like every other Pharma company. They are all having difficulty coming up with big blockbuster drugs. This company’s strong point is that it has a generic business that has done very well. Have a great business in eye care. He would step into this slowly. Not overly expensive.

biotechnology / pharmaceutical
Showing 1 to 15 of 41 entries

Novartis AG(NVS-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 1

Stockchase rating for Novartis AG is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novartis AG(NVS-N) Frequently Asked Questions

What is Novartis AG stock symbol?

Novartis AG is a American stock, trading under the symbol NVS-N on the New York Stock Exchange (NVS). It is usually referred to as NYSE:NVS or NVS-N

Is Novartis AG a buy or a sell?

In the last year, 1 stock analyst published opinions about NVS-N. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Novartis AG.

Is Novartis AG a good investment or a top pick?

Novartis AG was recommended as a Top Pick by on . Read the latest stock experts ratings for Novartis AG.

Why is Novartis AG stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novartis AG worth watching?

1 stock analyst on Stockchase covered Novartis AG In the last year. It is a trending stock that is worth watching.

What is Novartis AG stock price?

On 2021-10-19, Novartis AG (NVS-N) stock closed at a price of $83.15.